Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000228234 | SCV000285331 | benign | Tuberous sclerosis 2 | 2024-01-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000563194 | SCV000675625 | likely benign | Hereditary cancer-predisposing syndrome | 2016-07-18 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV001545292 | SCV001764598 | likely benign | not provided | 2018-10-16 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000228234 | SCV002039287 | benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000563194 | SCV002533366 | likely benign | Hereditary cancer-predisposing syndrome | 2020-09-16 | criteria provided, single submitter | curation | |
KCCC/NGS Laboratory, |
RCV000228234 | SCV004016164 | likely benign | Tuberous sclerosis 2 | 2023-07-07 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV003998819 | SCV004815062 | benign | Tuberous sclerosis syndrome | 2023-12-13 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001545292 | SCV005216994 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV004532847 | SCV004714190 | likely benign | TSC2-related disorder | 2023-12-15 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |